GlassScriptPhysician profile
David Edward Buechner
NPI 1619970688
$29,498.89
in general payments reported to CMS, 2019-2025
25 companies · $43.05 in 2025
The $43.05 reported for 2025 was less than what a typical Diagnostic Radiology provider received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $5,596 · 2021: $6,546 · 2022: $2,163 · 2023: $839 · 2025: $43.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $881.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $15,469.81 | 2019-2020 | |
| Medtronic, INC. | $6,920.19 | 2021-2023 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim, Osteocool Rf Ablation System |
| Galil Medical INC. | $1,707.30 | 2019 | |
| Stryker Corporation | $1,440.94 | 2019-2020 | |
| Relievant Medsystems, INC. | $1,230.10 | 2022-2023 | Intracept |
| Nevro Corp. | $484.70 | 2021-2022 | |
| Penumbra, INC. | $450.06 | 2019-2020 | |
| Abbott Laboratories | $359.87 | 2020-2023 | Proclaim |
| Boston Scientific Corporation | $218.81 | 2019-2025 | General - Pain Management, Patient Trial Kit |
| Inari Medical, INC. | $207.64 | 2019 | |
| Collegium Pharmaceutical, INC. | $146.43 | 2021-2023 | Belbuca, Xtampza |
| Biocompatibles, INC. | $142.90 | 2019 | |
| Genentech USA, INC. | $135.37 | 2019 | |
| Abbvie INC. | $135.02 | 2022 | |
| Biogen, INC. | $90.67 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $89.20 | 2022 | |
| Medtronic Vascular, INC. | $79.69 | 2020 | |
| Biotissue Holdings INC. | $56.46 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.32 | 2022 | |
| Nalu Medical, INC. | $32.74 | 2023 | Nalu Neurostimulation System |
| Vertos Medical, INC. | $19.64 | 2023 | Mild Device Kit |
| Scilex Pharmaceuticals INC. | $17.54 | 2021 | |
| Grt US Holding, INC. | $16.48 | 2021 | |
| Biodelivery Sciences International, INC. | $13.01 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$254,769.13 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Buechner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.